0001104659-23-122841.txt : 20231201 0001104659-23-122841.hdr.sgml : 20231201 20231201161644 ACCESSION NUMBER: 0001104659-23-122841 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231130 FILED AS OF DATE: 20231201 DATE AS OF CHANGE: 20231201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Golembiewski Michael Joseph CENTRAL INDEX KEY: 0001639479 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-22245 FILM NUMBER: 231459735 MAIL ADDRESS: STREET 1: 7 TURTLE CT CITY: FLEMINGTON STATE: NJ ZIP: 08822 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SEELOS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001017491 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870449967 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 293-2100 MAIL ADDRESS: STREET 1: 300 PARK AVENUE STREET 2: 2ND FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 FORMER COMPANY: FORMER CONFORMED NAME: APRICUS BIOSCIENCES, INC. DATE OF NAME CHANGE: 20100914 FORMER COMPANY: FORMER CONFORMED NAME: NEXMED INC DATE OF NAME CHANGE: 19970311 4 1 tm2331921-2_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-11-30 0 0001017491 SEELOS THERAPEUTICS, INC. SEEL 0001639479 Golembiewski Michael Joseph C/O SEELOS THERAPEUTICS, INC. 300 PARK AVENUE, 2ND FLOOR NEW YORK NY 10022 0 1 0 0 Chief Financial Officer 0 Common Stock 2023-11-30 4 P 0 83000 1.2075 A 86450 D The price reported in Column 4 is a weighted average purchase price. These shares were acquired in multiple open market transactions at prices ranging from $1.07 per share to $1.27 per share, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price. Effective on November 28, 2023, the Issuer conducted a reverse stock split at a ratio of 1-for-30 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split. /s/ Michael Golembiewski 2023-12-01